Active	Status	Sponsor type	Region	Phase	Filter
8 Active 1 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Goldenberg, Alec
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.	Recruiting	3	404	US	SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice	BriaCell Therapeutics Corporation	Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer	06/25	12/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia	Active, not recruiting	2	196	US	asciminib, ABL001	Novartis Pharmaceuticals	Chronic Myelogenous Leukemia - Chronic Phase	09/25	10/27
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab In combination with Bria-IMT for advanced breast cancer Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer Safety data in combination with Bria-IMT Dec 2018 - Dec 2018: Safety data in combination with Bria-IMT Anticipated efficiency data in combination with Bria-IMT Dec 2018 - Dec 2018: Anticipated efficiency data in combination with Bria-IMT More	Enrolling by invitation	1/2	36	US	SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012	BriaCell Therapeutics Corporation, LumaBridge	Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic	06/24	06/24
CIRLL study, NCT03420183: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies	Recruiting	1b	156	US	Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib	Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM)	B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma	04/19	12/22
Olimpio, James D
KontRASt-02, NCT05132075 / 2021-002605-10: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer	Active, not recruiting	3	96	Europe, Canada, US, RoW	JDQ443, docetaxel	Novartis Pharmaceuticals, Novartis Pharma AG	Non-Small Cell Lung Cancer	05/25	05/25
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids	Recruiting	3	150	Europe, Japan, US, RoW	Ianalumab, VAY736, Eltrombopag, ETB115, Placebo	Novartis Pharmaceuticals	Primary Immune Thrombocytopenia	08/25	05/28
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)	Recruiting	3	225	Europe, Japan, US, RoW	Ianalumab, VAY736, Placebo, Corticosteroids	Novartis Pharmaceuticals	Primary Immune Thrombocytopenia (ITP)	04/26	12/28
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia	Active, not recruiting	2	196	US	asciminib, ABL001	Novartis Pharmaceuticals	Chronic Myelogenous Leukemia - Chronic Phase	09/25	10/27